All stocks Β· APL
AP

ASSTON PHARMACEUTICALS LIMITED

APL BSE Drug Manufacturers - Specialty & Generic Healthcare

Asston Pharmaceuticals Limited manufactures pharmaceutical products in India, West Africa, South Africa, and Asian countries. The company provides tablets, such as aceclofenac, albendazole, aminophylline, artemether and…

ISIN INE0SJX01015
Listed β€”
Quarters tracked β€”
Filings 6 docs

About

Asston Pharmaceuticals Limited manufactures pharmaceutical products in India, West Africa, South Africa, and Asian countries. The company provides tablets, such as aceclofenac, albendazole, aminophylline, artemether and lumefantrine, ascorbic acid chewable, azithromycin, b-complex, calcium, cholecalciferol with folic acid, cefixime, cetirizine, ciprofloxacin, co-trimoxazole, cyproheptadine, dexamethasone, diclofenac, ferrous sulphate, folic acid, glucose, griseofulvin, levofloxacin, loperamide HCL, losartan potassium, mebendazole, metformin hydrochloride sustained release, metformin hydrochloride, metronidazole, multivitamin, nitrofurantoin, ofloxacin and ornidazole, pantoprazole, paracetamol, paracetamol, phenylephrine HCL, chlorpheniramine maleate and caffeine, prednisolone, pregabalin SR and methylcobalamin, pyridoxine HCL, rifampicin and isoniazid, rifampicin, isoniazid, pyrazinamide and ethambutol HCL, sildenafil, tadalafil, telmisartan, and zinc sulphate. It also offers capsules, including amoxicillin, ampicillin and cloxacillin, ampicillin, b-complex, cloxacillin, danazol, diclofenac, ibuprofen, paracetamol, caffeine, indomethacin, itraconazole, mecobalamin, alpha lipoic acid, thiamine mononitrate, pyridoxine HCL and folic acid, mefenamic acid, multivitamin, omeprazole, pregabalin, rabeprazole sodium and domperidone SR, rifabutin, and rifampicin; and oral suspension and syrup, which includes albendazole, amodiaquine, antacid, artemether and lumefantrine dry, azithromycin dry, b-complex, cefixime dry, chloroquine, co-trimoxazole, iron, kids cold, kids cough, mebendazole, metronidazole, multivitamin, and paracetamol. In addition, the company provides sachets and oral powder comprising oral rehydration salt, vitamin d3, glucose powder, sorbitol powder, prebiotic and probiotic, and antacids. It sells its products in the form of tablet capsules, syrup, sachet, and injection. The company was incorporated in 2019 and is based in Navi Mumbai, India.

Quarterly Results

No quarterly results synced yet for this stock.

Data is backfilled from screener.in β€” check back soon.

Profit & Loss

Annual Β· Rs. Crores
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Sales 25.4725.0416.036.549.60
Expenses 26.0419.6012.215.029.96
Operating Profit -0.575.443.821.52-0.36
OPM % -2.2421.7323.8323.24-3.75
Other Income 6.120.570.250.650.96
Interest 0.630.950.760.720.43
Depreciation 0.320.040.060.040.01
Profit before tax 4.605.023.251.410.16
Tax % 15.8723.1125.2325.5331.25
Net Profit 3.873.852.431.060.11
EPS in Rs 4.556.1431.0015.141.57
Dividend Payout % 0.000.000.000.000.00

Balance Sheet

Annual Β· Rs. Crores β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Equity Capital 8.516.270.780.700.70
Reserves 30.354.766.401.290.23
Borrowings 5.117.256.825.243.31
Other Liabilities 7.689.846.706.465.25
Total Liabilities 51.6528.1220.7013.699.49
Fixed Assets 10.690.960.971.130.92
CWIP 0.000.000.000.000.00
Investments 0.000.000.000.000.00
Other Assets 40.9627.1619.7312.568.57
Total Assets 51.6528.1220.7013.699.49

Cash Flows

Annual Β· Rs. Crores β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Cash from Operating Activity -10.18-0.03-3.97-0.32-1.19
Cash from Investing Activity -9.910.73-0.01-0.910.00
Cash from Financing Activity 21.18-0.513.861.211.29
Net Cash Flow 1.090.19-0.12-0.010.10
Free Cash Flow -20.24-0.06-3.98-0.57-1.19
CFO/OP % 1,368.000.00-92.00-20.00322.00

Ratios

Annual Β· Days / % β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Debtor Days 524.07357.86380.71480.53243.33
Inventory Days 16.1418.5953.91204.2927.24
Days Payable 120.76154.11217.50754.51246.78
Cash Conversion Cycle 419.45222.34217.12-69.7023.79
Working Capital Days 434.22178.86162.8043.53-12.17
ROCE % 16.8036.6237.7837.14β€”

Shareholding Pattern

% holding β€” latest first
Holder Mar 2026 Sep 2025
Promoters 50.66 50.66
FIIs 1.91 6.04
Public 47.41 43.30
No. of Shareholders 687 751

Corporate Actions

No corporate actions recorded.

Announcements

5 filings